Sanofi: Rectal Neoplasms trials
The registry lists 10 Rectal Neoplasms studies with Sanofi as lead sponsor. 1 are open to participants now and 2 have results posted.
Phase 1 3Phase 2 8Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
- Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal CancerCompletedNCT00851084Phase 2Results posted
- A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in PatientsCompletedNCT00454116Phase 2Results posted
- Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal CancerCompletedNCT00421824Phase 2
- Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal CancerCompletedNCT00403624Phase 1/2
- Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal CancerCompletedNCT00263029Phase 2
- Oxaliplatin in Rectal CancerTerminatedNCT00259363Phase 1/2
- CORE: Capecitabine, Oxaliplatin, Radiotherapy and ExcisionCompletedNCT00174616Phase 2
- Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal CancerCompletedNCT00012389Phase 3
- Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal CancerStatus unknownNCT00008281Phase 3